...
首页> 外文期刊>Diabetes >Glucokinase Is a Critical Regulator of Ventromedial Hypothalamic Neuronal Glucosensing
【24h】

Glucokinase Is a Critical Regulator of Ventromedial Hypothalamic Neuronal Glucosensing

机译:葡萄糖激酶是下丘脑下丘脑神经元葡萄糖敏感的关键调节剂。

获取原文
获取原文并翻译 | 示例
           

摘要

To test the hypothesis that glucokinase is a critical regulator of neuronal glucosensing, glucokinase activity was increased, using a glucokinase activator drug, or decreased, using RNA interference combined with calcium imaging in freshly dissociated ventromedial hypothalamic nucleus (VMN) neurons or primary ventromedial hypothal-amus (VMH; VMN plus arcuate nucleus) cultures. To assess the validity of our approach, we first showed that glucose-induced (0.5-2.5 mmol/l) changes in intracellular Ca~(2+) concentration ([Ca~(2+)]_i) oscillations, using fura-2 and changes in membrane potential (using a membrane potential-sensitive dye), were highly correlated in both glucose-excited and -inhibited neurons. Also, glucose-excited neurons increased (half-maximal effective concentration [EC_(50)] = 0.54 mmol/l) and glucose-inhibited neurons decreased (half-maximal inhibitory concentration [IC_(50)] = 1.12 mmol/l) [Ca~(2+)]_i oscillations to incremental changes in glucose from 0.3 to 5 mmol/l. In untreated primary VMH neuronal cultures, the expression of glucokinase mRNA and the number of demonstrable glucosensing neurons fell spontaneously by half over 12-96 h without loss of viable neurons. Transfection of neurons with small interfering glucokinase RNA did not affect survival but did reduce glucokinase mRNA by 90% in association with loss of all demonstrable glucose-excited neurons and a 99% reduction in glucose-inhibited neurons. A pharmacological glucokinase activator produced a dose-related increase in [Ca~(2+)]_i oscillations in glucose-excited neurons (EC_(50) = 0.98 mmol/l) and a decrease in glucose-inhibited neurons (IC_(50) = 0.025 μmol/l) held at 0.5 mmol/l glucose. Together, these data support a critical role for glucokinase in neuronal glucosensing.
机译:为了检验以下假设:葡萄糖激酶是神经元葡萄糖激酶的关键调节剂,在刚分离的腹膜下丘脑核(VMN)神经元或原发性腹膜下丘脑神经元中,使用葡萄糖激酶激活剂可提高或降低葡萄糖激酶活性,可使用RNA干扰结合钙干扰来降低葡萄糖激酶活性。 mus(VMH; VMN加弓形核)培养物。为了评估我们方法的有效性,我们首先使用fura-2表明葡萄糖诱导的细胞内Ca〜(2+)浓度([Ca〜(2 +)] _ i)振荡变化(0.5-2.5 mmol / l)葡萄糖兴奋的神经元和抑制​​的神经元中膜电位的变化(使用膜电位敏感的染料)高度相关。另外,葡萄糖激发的神经元增加(最大最大有效浓度[EC_(50)] = 0.54 mmol / l),而葡萄糖抑制的神经元减少(最大最大抑制浓度[IC_(50)] = 1.12 mmol / l)[ Ca〜(2 +)] _ i振荡,葡萄糖从0.3到5 mmol / l逐渐增加。在未经处理的原发性VMH神经元培养物中,葡萄糖激酶mRNA的表达和可证实的糖化神经元数量在12-96小时内自发下降了一半,而没有丧失存活的神经元。用小的干扰葡萄糖激酶RNA转染神经元并不会影响存活率,但确实使葡萄糖激酶mRNA降低了90%,这与所有可证实的葡萄糖激发神经元的损失以及葡萄糖抑制神经元减少了99%有关。药理学的葡萄糖激酶激活剂在葡萄糖兴奋的神经元(EC_(50)= 0.98 mmol / l)中产生与剂量相关的[Ca〜(2 +)] _ i振荡,而在葡萄糖抑制的神经元中减少(IC_(50) = 0.025μmol/ l)的葡萄糖浓度保持在0.5 mmol / l。总之,这些数据支持了葡萄糖激酶在神经元葡萄糖代谢中的关键作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号